ES2283744T3 - Metodos y composiciones para el tratamiento de condiciones hiperproliferativas. - Google Patents

Metodos y composiciones para el tratamiento de condiciones hiperproliferativas. Download PDF

Info

Publication number
ES2283744T3
ES2283744T3 ES03702642T ES03702642T ES2283744T3 ES 2283744 T3 ES2283744 T3 ES 2283744T3 ES 03702642 T ES03702642 T ES 03702642T ES 03702642 T ES03702642 T ES 03702642T ES 2283744 T3 ES2283744 T3 ES 2283744T3
Authority
ES
Spain
Prior art keywords
pyrimidin
phenyl
benzyloxy
pyrrolo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03702642T
Other languages
English (en)
Spanish (es)
Inventor
Charles Dean Stiles
Carlos Garcia-Echeverria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2283744T3 publication Critical patent/ES2283744T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES03702642T 2002-02-14 2003-02-14 Metodos y composiciones para el tratamiento de condiciones hiperproliferativas. Expired - Lifetime ES2283744T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35691202P 2002-02-14 2002-02-14
US356912P 2002-02-14

Publications (1)

Publication Number Publication Date
ES2283744T3 true ES2283744T3 (es) 2007-11-01

Family

ID=27734705

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03702642T Expired - Lifetime ES2283744T3 (es) 2002-02-14 2003-02-14 Metodos y composiciones para el tratamiento de condiciones hiperproliferativas.

Country Status (11)

Country Link
EP (1) EP1476192B1 (enExample)
JP (1) JP5053503B2 (enExample)
CN (1) CN100591355C (enExample)
AT (1) ATE360442T1 (enExample)
AU (1) AU2003205768A1 (enExample)
BR (1) BR0307629A (enExample)
CA (1) CA2476000A1 (enExample)
DE (1) DE60313434T2 (enExample)
ES (1) ES2283744T3 (enExample)
PT (1) PT1476192E (enExample)
WO (1) WO2003068265A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
DE4129533A1 (de) * 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CN1117097C (zh) * 1998-05-29 2003-08-06 北京金赛狮生物制药技术开发有限责任公司 类胰岛素生长因子受体基因的反义核酸的抑癌作用

Also Published As

Publication number Publication date
DE60313434D1 (de) 2007-06-06
DE60313434T2 (de) 2008-01-10
EP1476192A1 (en) 2004-11-17
ATE360442T1 (de) 2007-05-15
EP1476192B1 (en) 2007-04-25
JP2005517040A (ja) 2005-06-09
CA2476000A1 (en) 2003-08-21
BR0307629A (pt) 2005-01-11
JP5053503B2 (ja) 2012-10-17
PT1476192E (pt) 2007-07-26
WO2003068265A1 (en) 2003-08-21
CN1630534A (zh) 2005-06-22
CN100591355C (zh) 2010-02-24
AU2003205768A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
PT1476192E (pt) Métodos e composições para tratar condições hierproliferativas
ES2733348T3 (es) Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
ES2368741T3 (es) Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
US8119649B2 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
EP2606890A1 (en) Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
US20110312978A1 (en) Pde1 inhibitors for ophthalmic disorders
JP2015212303A (ja) 有機化合物
US20140336180A1 (en) Combination of mek inhibitors and selective inhibitors of aurora a kinase
JP2014503566A5 (enExample)
MXPA06008157A (es) Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
US20130040972A1 (en) USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA
US20050215564A1 (en) Methods and compositions for treating hyperproliferative conditions
ES2445896T3 (es) Uso de un inhibidor de quinasa para el tratamiento del timoma
WO2007115286A2 (en) Combinations of therapeutic agents for treating cancer
ES3055126T3 (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
ES2303585T3 (es) Combinacion de glivec(sti571) con un inhibidor de quinasa dependiente de ciclina, especialmente flavopiridol en el tratamiento de cancer.
JPH01160919A (ja) 鎮痛剤
AU2011202950B2 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
JP2007517854A (ja) Ｃｒｆアンタゴニスト及び５−ｈｔ１ｂ受容体アンタゴニストの組み合わせ
ZA200306404B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative.